Items Tagged ‘afinitor’

April 4, 2018

Precision Cancer Treatment with Afinitor Encouraging in Uterine Cancer

By

CancerConnect News: Combination therapy with Afinitor (everolimus) and Femara (letrozole) demonstrated encouraging activity in the treatment of advanced endometrial cancer, according to a report from the Society of Gynecologic Oncologists meeting this week. About Uterine (Endometrial) Cancer Uterine cancer is one of the most common gynecologic cancers in women, with more than 67,000 individuals diagnosed […]

View full entry

Tags: afinitor, endometrial cancer treatment, Femara, mtor, News, Precision Cancer Medicine, Uterine Cancer, uterine cancer treatment


November 9, 2017

Checkpoint Inhibitors Improve Outcomes of Renal Cell Cancer

By

Opdivo (nivolumab) a novel “checkpoint” inhibitor immunotherapy has been demonstrated to produce superior three year survival benefit for patients with previously treated advanced renal cell carcinoma (RCC).1 Treatment options for RCC continue to expand and are associated with improved outcomes. About Renal Cell Carcinoma Renal cell carcinoma accounts for more than 100,000 deaths worldwide each […]

View full entry

Tags: afinitor, checkpoint inhibitor, everolimus, immunotherapy, metastatic kidney cancer, News, opdivo, PD-1, Precision Cancer Medicine, Renal Cancer


February 5, 2015

Afinitor® plus Herceptin® and Paclitaxel Effective in Advanced Hormone Receptor-Negative HER2-Positive Breast Cancer

By

The combination of Afinitor® (everolimus) plus Herceptin® (trastuzumab) paclitaxel appears effective for patients with advanced HER2-positive breast cancer that is hormone receptor (HR)-negative. These findings were presented at the 2014 San Antonio Breast Cancer Symposium, December 9–13, in San Antonio, Texas. Afinitor is an oral medication that works by inhibiting a protein known as mTOR. […]

View full entry

Tags: afinitor, Breast Cancer, herceptin, paclitaxel